- Home
- KBH vs GH Comparison
KBH vs GH Comparison
Compare KBH & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBH
- GH
- Stock Information
- Founded
- KBH 1957
- GH 2011
- Country
- KBH United States
- GH United States
- Employees
- KBH N/A
- GH N/A
- Industry
- KBH Homebuilding
- GH Medical Specialities
- Sector
- KBH Consumer Discretionary
- GH Health Care
- Exchange
- KBH Nasdaq
- GH Nasdaq
- Market Cap
- KBH 4.6B
- GH 4.9B
- IPO Year
- KBH 1987
- GH 2018
- Fundamental
- Price
- KBH $65.02
- GH $57.19
- Analyst Decision
- KBH Hold
- GH Strong Buy
- Analyst Count
- KBH 13
- GH 17
- Target Price
- KBH $67.88
- GH $58.24
- AVG Volume (30 Days)
- KBH 1.2M
- GH 2.3M
- Earning Date
- KBH 09-24-2025
- GH 11-05-2025
- Dividend Yield
- KBH 1.53%
- GH N/A
- EPS Growth
- KBH 0.49
- GH N/A
- EPS
- KBH 7.59
- GH N/A
- Revenue
- KBH $6,673,869,000.00
- GH $828,849,000.00
- Revenue This Year
- KBH N/A
- GH $28.07
- Revenue Next Year
- KBH N/A
- GH $21.61
- P/E Ratio
- KBH $8.59
- GH N/A
- Revenue Growth
- KBH 3.65
- GH 28.74
- 52 Week Low
- KBH $48.90
- GH $20.14
- 52 Week High
- KBH $89.70
- GH $68.00
- Technical
- Relative Strength Index (RSI)
- KBH 55.09
- GH 48.85
- Support Level
- KBH $64.27
- GH $53.40
- Resistance Level
- KBH $67.52
- GH $61.95
- Average True Range (ATR)
- KBH 1.73
- GH 2.52
- MACD
- KBH -0.29
- GH -1.24
- Stochastic Oscillator
- KBH 42.61
- GH 25.96
About KBH KB Home
KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.